Pharmacogenomics study shows link between testing and better health outcomes

By Kate McCaffery | Sept. 24, 2020, 9:37 a.m.

Photo: Freepik

“The question we were trying to answer was if clinicians are provided access to pharmacogenomic test results during routine clinical care, would patient outcomes improve?”

This article is reserved to PRO Level subscribers

Discover the PRO Level

The most popular in Health

Workers report rising levels of burnout

Long COVID-19 is an unmet burden on the healthcare system

Moody’s report examines link between mental health and medical costs

Headlines

MIB acquiring the APEXA compliance platform

Intact’s net income down 13 per cent

The Co-operators’ net income falls 33.2 per cent

Related topics …

GREEN SHIELD CANADA

Disability claims due to mental health issues on the rise

Green Shield seeking to become the main care provider in Canada

Green Shield Canada makes two acquisitions

Group insurance sales slide

HBM+

Green Shield study confirms benefits of pharmacogenomic testing

Green Shield harnesses artificial intelligence to detect and prevent benefits fraud

Medication

Long COVID-19 is an unmet burden on the healthcare system

Alzheimer Society releases recommendations for dementia patients

Medavie Blue Cross shares benefits plan data

$206 million in compensation for doctor errors in 2020

Magazine supplement

Disability insurance: How do 16 products from seven providers stack up?

Advisors need ESG training

Business value index for individual life insurance clienteles

100 buyers for every seller

Pharmacogenomics study shows link between testing and better health outcomes

Choose your payment method

Confirmation